(MENAFNEditorial) GENEVA Switzerland August 8 2014/African Press Organization (APO)/ -- Epidemiology and surveillance
Between 5 and 6 August 2014 a total of 68 new cases of Ebola virus disease (laboratory-confirmed probable and suspect cases) as well as 29 deaths were reported from Guinea Liberia Nigeria and Sierra Leone.
Health sector response
On Wednesday 6 August and Thursday 7 August an Emergency Committee was held via teleconference to determine whether the current outbreak constitutes a Public Health Emergency of International Concern. After discussion and deliberation on the information provided the Committee advised that:
the Ebola outbreak in West Africa constitutes an 'extraordinary event' and a public health risk to other States;
the possible consequences of further international spread are particularly serious in view of the virulence of the virus the intensive community and health facility transmission patterns and the weak health systems in the currently affected and most at-risk countries.
a coordinated international response is deemed essential to stop and reverse the international spread of Ebola.
It was the unanimous view of the Committee that the conditions for a Public Health Emergency of International Concern (PHEIC) have been met.
On Friday 8 August the Director-General Dr Margaret Chan gave a press briefing to the international media from WHO Headquarters. Dr Chan will give an additional briefing on the situation of the outbreak and the ongoing response in the region to the Permanent and Observer Missions to the United Nations and other international organizations in Geneva on Tuesday 12 August. Permanent Representatives of the affected countries have been invited to speak on behalf of their respective Governments on the national Ebola response and priorities.
On Monday 11 August WHO will convene a panel of medical ethics experts to begin looking at the use of experimental treatments in the ongoing EVD outbreak in West Africa. At this time there are no registered medicines or vaccines against this deadly virus; several experimental options are currently under development though. The recent treatment of two health workers from US faith-based aid organizations has raised questions about whether medicines that have never been tested or shown to be safe in humans should be used in outbreak situations. In the case of Ebola supplies are extremely limited which then raises questions about who should receive it if it's used.
Disease update
New cases and deaths attributable to EVD continue to be reported by the Ministries of Health in Guinea Liberia Nigeria and Sierra Leone. Between 5 and 6 August 2014 68 new cases (laboratory-confirmed probable and suspect cases) of EVD and 29 deaths were reported from the four countries as follows: Guinea 0 new cases and 4 deaths; Liberia 38 new cases and 12 deaths; Nigeria 4 new cases and 1 death; and Sierra Leone 26 new cases and 12 deaths.
As of 6 August 2014 the cumulative number of cases attributed to EVD in the four countries stands at 1 779 including 961 deaths. The distribution and classification of the cases are as follows: Guinea 495 cases (355 confirmed 133 probable and 7 suspected) including 367 deaths; Liberia 554 cases (148 confirmed 274 probable and 132 suspected) including 294 deaths; Nigeria 13 cases (0 confirmed 7 probable and 6 suspected) including 2 deaths; and Sierra Leone 717 cases (631 confirmed 38 probable and 48 suspected) including 298 deaths.
The total number of cases is subject to change due to ongoing reclassification retrospective investigation and availability of laboratory results. Data reported in the Disease Outbreak News are based on official information reported by Ministries of Health.
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.